Adjuvant therapy of pancreatic cancer

Journal of the Pancreas

Volumn 13, Issue 4, 2012, Pages 349-353

  Chaulagain, Chakra P ^a   Ng, John ^b   Wazer, David ^a   Saif, Muhammad Wasif ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b New York Presbyterian Hospital ^*  (United States)

Author keywords

Adjuvant; Chemotherapy; Immunotherapy; Pancreatic neoplasms

Indexed keywords

ALGENPANTUCEL L; CAPECITABINE; FLUOROURACIL; GEMCITABINE; K RAS PROTEIN; PACLITAXEL; SMAD4 PROTEIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DOSIMETRY; DPC4 GENE; DRUG EFFICACY; GENOTYPING TECHNIQUE; HUMAN; MULTIPLE CYCLE TREATMENT; ONCOGENE; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS SURGERY; PROTON THERAPY; RADIATION INJURY; THERAPY EFFECT; TREATMENT DURATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

HUMANS; IMMUNOTHERAPY; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTONS; RAS PROTEINS;

EID: 84864497372     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Deshpande V, et al. Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head. J Clin Oncol 2012; 30(Suppl):Abstract 4021.
2. Alvarez-Gallego R, Cubillo A, Rodriguez-Pascual J, Quijano Y, De Vicente E, García L, et al. Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer. J Clin Oncol 2012; 30(Suppl):Abstract 4040.
3. Hardacre JM, Mulcahy MF, Small W, Talamonti MS, Obel JC, Rocha Lima CMS, et al. Addition of algenpantucel-Limmunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer. J Clin Oncol 2012; 30(Suppl):Abstract 4049.
4. Sinn M, Sinn BV, Striefler JK, Stieler J, Niedergethmann M, Gellert K, et al. Long-term survival in patients with pancreatic cancer: Relevant factors in CONKO-001. J Clin Oncol 2012; 30(Suppl):Abstract 4020.
5. Steinberg ML, Konski A. Proton beam therapy and the convoluted pathway to incorporating emerging technology into routine medical care in the United States. Cancer J. 2009;15:333-8.
6. Koidoet A. Current Immunotherapeutic Approaches in Pancreatic Cancer. Clinical and Developmental Immunology. June, 2011
7. Saif MW. JOP. J Pancreas (Online) 2011 Mar 9; 12(2):106-109. Adjuvant Therapy of Pancreatic Cancer: Beyond Gemcitabine. Highlights from the 2011 ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, USA. January 20-22, 2011
8. Hardacre et. Al. Effect of the addition of algenpantucel-L immunotherapy to standard adjuvant therapy on survival in patients with resected pancreas cancer. J Clin Oncol 2011; 29(Suppl 4):Abstract 236.
9. Herman et a. Correlation of DPC4 status with outcomes in pancreatic adenocarcinoma patients receiving adjuvant chemoradiation. J Clin Oncol 2011; 29(Suppl 4):Abstract 168.